Pyratape P Horse Wormer 40% w/w Oral Paste

Maa: Yhdistynyt kuningaskunta

Kieli: englanti

Lähde: VMD (Veterinary Medicines Directorate)

Aktiivinen ainesosa:

Pyrantel Embonate

Saatavilla:

Bimeda Animal Health Limited

ATC-koodi:

QP52AF02

INN (Kansainvälinen yleisnimi):

Pyrantel Embonate

Lääkemuoto:

Oral paste

Prescription tyyppi:

POM-VPS -Prescription Only Medicine – Veterinarian, Pharmacist, Suitably Qualified Person

Terapeuttinen ryhmä:

Horses

Terapeuttinen alue:

Anthelmintic

Valtuutuksen tilan:

Authorized

Valtuutus päivämäärä:

1996-08-02

Valmisteyhteenveto

Revised: October 2018
AN: 00830/2018
Page 1 of 5
SUMMARY OF PRODUCT CHARACTERISTICS
1.
NAME OF VETERINARY MEDICINAL PRODUCT
Pyratape P Horse Wormer
40% w/w Oral Paste
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Active Substance
Per Syringe
Pyrantel embonate
11.4g
Excipients
Butylated Hydroxytoluene
0.0057g
For full list of excipients, please see section 6.1.
3.
PHARMACEUTICAL FORM
Oral Paste
Pale yellow to buff coloured paste
4.
CLINICAL PARTICULARS
4.1
TARGET SPECIES
Horses and ponies.
4.2
INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES
Pyrantel embonate is a broad spectrum anthelmintic. Pyrantel embonate
is indicated for use in the horse for the control and treatment of
adult
infections of large and small strongyles, Pinworms, Roundworms,
Tapeworms.
Pyrantel embonate has a broad spectrum of activity, including activity
against:
Large strongyles:
_Stronglylus vulgaris, S. edentatus, S. equinus._
Small strongyles:
_Trichonema spp. (Cyathostomes), Triodontophorus _
_spp._
Pinworms:
_Oxyuris equi, Probstmayria vivipara._
Large roundworms:
_Parascaris equorum._
Tape worms:
_Anoplocephala perfoliata._
Revised: October 2018
AN: 00830/2018
Page 2 of 5
4.3
CONTRA-INDICATIONS
Not for use in foals less than 4 weeks of age.
Contraindicated in known sensitivity to pyrantel and in severely
debilitated
animals.
4.4
SPECIAL WARNINGS FOR EACH TARGET SPECIES.
Care should be taken to avoid the following practices because they
increase the risk of development of resistence and could ultimately
result
in ineffective therapy:
�
Too frequent and repeated use of anthelmintics from the same
class, over an extended period of time.
�
Underdosing, which may be due to underestimation of weight,
misadministeration of the product, or lack of calibration of the
dosing device(if any).
Suspected clinical cases of resistence to anthelmintics should be
further
investigated using appropriate tests (e.g. Faecal Egg Count Reduction
Test). Where the results of the test(s) strongly suggest resistance to
a
particular
anthelminitc,
an
anthelminti